STI Stock Trade Intelligence
IPD

IMPEDIMED LIMITED

Health Care · ASX:IPD
$0.0040
0.00%
Market cap
$15M
Turnover
$82
Last price
$0.0040
Day change
0.00%
Announcements
13
Range, past year
Open 0.040 · Low 0.003 · Now 0.004 · High 0.059
Open IPD in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

IPD momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
25/100
Wyckoff phase
Accumulation2d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+33.3%
1 Month
-33.3%
1 Year
-89.7%
RSI
46
Avg daily range
17.2%

IMPEDIMED LIMITED scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 2 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -57.1%
  • High volatility (ATR 17.2%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
IPD appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

IPD announcements

Recent price-sensitive releases.
  • 2026-10-30 Quarterly Activities Report and Appendix 4C - Sep-2026 Qtr Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-08-27 Appendix 4E Preliminary Final Report
  • 2026-07-28 Quarterly Activities Report and Appendix 4C - Jun-2026 Qtr Commitments Test Entity - Fourth Quarter Activity Report | Web Cast | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-06-10 Oversubscribed Share Purchase Plan Successfully Completed
  • 2026-06-02 CEO Business Update
  • 2026-05-04 ImpediMed announces a successful $15.2 million Capital Raise
  • 2026-05-04 Equity Raising Investor Presentation
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.